May 19, 2026 — Vie Ventures was featured in In Vivo for its work addressing a persistent funding gap in autoimmune and immune-mediated disease innovation. The article highlights Vie’s strategy of backing companies advancing from preclinical development into early clinical proof, working alongside existing investors, disease advocacy organizations, and mission-aligned families to help promising science reach patients faster. Vie also discussed its focus on shared immune biology: the idea that insights from one autoimmune or immune-mediated disease can unlock therapeutic progress across many others.